Treatment Assignment of High-Risk Symptomatic Severe Aortic Stenosis Patients Referred for Transcatheter AorticValve Implantation

Transcatheter aortic valve implantation (TAVI) has become an option for patients with symptomatic severe aortic stenosis whose co-morbidities place them at high surgical risk. However, little is known regarding treatment allocation. From May 2008 to May 2011, all high-risk patients with symptomatic...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2013-07, Vol.112 (1), p.100-103
Main Authors: Bainey, Kevin R., MD, Natarajan, Madhu K., MD, MSc, Mercuri, Mathew, MSc, Lai, Tony, MD, Teoh, Kevin, MD, Chu, Victor, MD, Whitlock, Richard P., MD, PhD, Velianou, James L., MD
Format: Article
Language:English
Subjects:
Aged, 80 and over
Aortic Valve - surgery
Aortic Valve Stenosis - surgery
Cardiac Catheterization
Cardiology
Cardiovascular
Cardiovascular disease
Comorbidity
Coronary vessels
Echocardiography
Female
Heart attacks
Heart Valve Prosthesis
Heart Valve Prosthesis Implantation - methods
Humans
Male
Mortality
Prospective Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transcatheter aortic valve implantation (TAVI) has become an option for patients with symptomatic severe aortic stenosis whose co-morbidities place them at high surgical risk. However, little is known regarding treatment allocation. From May 2008 to May 2011, all high-risk patients with symptomatic severe aortic stenosis referred to an experienced single-center TAVI clinic were reviewed. A total of 170 consecutive patients were evaluated. Of these, 58 (34%) were accepted for TAVI (mean age 81 ± 8 years). Thirty-three patients (19%) were accepted for conventional aortic valve replacement (AVR; mean age 83 ± 6 years). Sixty-two patients (37%) were treated conservatively (mean age 83 ± 6 years). Seventeen patients (10%) died awaiting complete assessment. At 30 days, all-cause mortality was 10% in the TAVI group, 3% in the conventional AVR group, and 32% in the conservatively treated group. Multivariate-adjustment identified the absence of chronic obstructive pulmonary disease (hazard ratio 0.30, 95% confidence interval 0.09 to 0.98, p 
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2013.02.062